Page last updated: 2024-12-11

methoxysuccinyl-alanyl-alanyl-prolyl-valine chloromethyl ketone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methoxysuccinyl-alanyl-alanyl-prolyl-valine chloromethyl ketone: prevents elastase-induced emphysema [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methoxysuccinyl-Ala-Ala-Pro-Val chloromethyl ketone : A tripeptide derived from methoxysuccinyl-Ala-Ala-Pro-Val by conversion of the terminal carboxy group to the corresponding chloromethyl ketone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5486692
CHEMBL ID2311166
CHEBI ID83803
MeSH IDM0087439

Synonyms (24)

Synonym
65144-34-5
meosuc-ala-ala-pro-val-chloromethylketone
meosuc-ala-ala-pro-val-cmk
n-(methoxysuccinyl)-ala-ala-pro-val-chloromethyl ketone, elastase inhibitor
meosuc-aapv-cmk
elastase inhibitor iii
msaapvck
methoxysuccinyl-alanyl-alanyl-prolyl-valine chloromethyl ketone
l-prolinamide, n-(4-methoxy-1,4-dioxobutyl)-l-alanyl-l-alanyl-n-(3-chloro-1-(1-methylethyl)-2-oxopropyl)-, (s)-
methoxy-suc-ala-ala-pro-val-chloromethyl ketone
methyl 4-[[(2s)-1-[[(2s)-1-[(2s)-2-[[(3s)-1-chloro-4-methyl-2-oxopentan-3-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoate
elastase inhibitor, spck
n-(methoxysuccinyl)-ala-ala-pro-val-chloromethyl ketone
chebi:83803 ,
CHEMBL2311166 ,
methoxysuccinyl-ala-ala-pro-val chloromethyl ketone
meosuc-ala-ala-pro-val-ch2cl
n-(4-methoxy-4-oxobutanoyl)-l-alanyl-l-alanyl-n-[(3s)-1-chloro-4-methyl-2-oxopentan-3-yl]-l-prolinamide
bdbm50454654
mfcd00077136
DTXSID40215459
Q27157243
methyl 4-((s)-1-((s)-1-((s)-2-((s)-1-chloro-4-methyl-2-oxopentan-3-ylcarbamoyl)pyrrolidin-1-yl)-1-oxopropan-2-ylamino)-1-oxopropan-2-ylamino)-4-oxobutanoate
PD194482

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"A pharmacokinetic model is described for testing of polymorphonuclear leukocyte (PMN) elastase inhibitors administered by intratracheal or aerosol dosing of hamsters."( A comparison of alpha 1-proteinase inhibitor methoxysuccinyl-Ala-Ala-Pro-Val-chloromethylketone and specific beta-lactam inhibitors in an acute model of human polymorphonuclear leukocyte elastase-induced lung hemorrhage in the hamster.
Ashe, BM; Davies, P; Dellea, PS; Doherty, JB; Finke, PE; Fletcher, DS; Hagmann, W; Hand, KM; Mumford, RA; Osinga, DG, 1990
)
0.28
" A dose-response relationship was observed in the kinetics of substrate hydrolysis catalyzed by three elastases: porcine pancreatic elastase, which was employed to model this approach; human leukocyte elastase; and elastase in human chronic wound fluid."( Inhibition of elastase by a synthetic cotton-bound serine protease inhibitor: in vitro kinetics and inhibitor release.
Batiste, S; Bopp, AF; Cohen, IK; Diegelmann, RF; Edwards, JV; Montante, SJ; Ullah, AJ,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.4.21.37 (leukocyte elastase) inhibitorAn EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the activity of leukocyte elastase (EC 3.4.21.37).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
alpha-chloroketoneA chloroketone in which the chlorine and oxo substituents are on adjacent carbon atoms.
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chymotrypsin-like elastase family member 2ASus scrofa (pig)IC50 (µMol)500.00002.18522.34262.5000AID159692
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID159692Inhibition of Human Leukocyte Elastase1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
7-alkylidenecephalosporin esters as inhibitors of human leukocyte elastase.
AID1708723Inhibition KCN-induced elastase like activity in human U-937 cells at 0.01 to 100 uM using substrate MAAPV2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both
AID1708728Protection against necrosis in C57BL/6J mouse model of traumatic brain injury assessed as decrease in neuronal damage in brain at 100 ug, icv measured 1 hr post injury by neurological severity score based analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both
AID1708725Protection against KCN-induced necrosis in human PC-12 cells assessed as reduction in KCN-induced cell death at 10 to 300 uM incubated for 5 hrs by LDH release assay2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both
AID1708727Toxicity in sham control C57BL/6J mouse at 100 ug, icv2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both
AID1819020Inhibition of elastase (unknown origin) at 2.5 uM by fluorescence microtiter plate method relative to control2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Elastase Inhibitor Cyclotheonellazole A: Total Synthesis and In Vivo Biological Evaluation for Acute Lung Injury.
AID1708729Protection against necrosis in C57BL/6J mouse model of traumatic brain injury assessed as decrease in necrotic space in brains at 100 ug, icv measured 24 hrs post injury by TTC staining based analysis2021Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3
Targeting Necrosis: Elastase-like Protease Inhibitors Curtail Necrotic Cell Death Both
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (33.33)18.7374
1990's12 (44.44)18.2507
2000's3 (11.11)29.6817
2010's1 (3.70)24.3611
2020's2 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.92 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]